TheraQuest's TQ-1019 shows sustained efficacy in animals

TheraQuest Biosciences, a US development-stage drugmaker, presented encouraging data on TQ-1019, its proprietary topical local anesthetic and on Securel, its abuse deterrent opiod formulation technology, at the 12th World Congress of the International Association for the Study of Pain, in Glasgow, Scotland.

Studies of TQ-1019 show that topical application provides rapid onset and sustained efficacy in animal models of painful HIV-neuropathy due to the HIV viral envelope protein gp120 and the antiretroviral drug zalcitabine. Both have been implicated in painful HIV-associated peripheral neuropathy.